Top

Published in:

Open Access 01-12-2010 | Short report

Evaluation of adenovirus capsid labeling versus transgene expression

Authors: Jing Li, Aiman Fatima, Svetlana Komarova, Hideyo Ugai, Priyanka Uprety, Justin C Roth, Minghui Wang, Robert A Oster, David T Curiel, Qiana L Matthews

Published in: Virology Journal | Issue 1/2010

Abstract

Adenoviral vectors have been utilized for a variety of gene therapy applications. Our group has incorporated bioluminescent, fluorographic reporters, and/or suicide genes within the adenovirus genome for analytical and/or therapeutic purposes. These molecules have also been incorporated as capsid components. Recognizing that incorporations at either locale yield potential advantages and disadvantages, our report evaluates the benefits of transgene incorporation versus capsid incorporation. To this end, we have genetically incorporated firefly luciferase within the early region 3 or at minor capsid protein IX and compared vector functionality by means of reporter readout.

Available only for authorised users

Kay MA, Glorioso JC, Naldini L: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001, 7: 33-40. 10.1038/83324PubMedCrossRef

Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998, 72: 9706-9713.PubMedPubMedCentral

Matthews QL, Sibley DA, Wu H, Li J, Stoff-Khalili MA, Waehler R, Mathis JM, Curiel DT: Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging 2006, 5: 510-519.PubMedPubMedCentral

Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M, Curiel DT: Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging 2004, 3: 105-116. 10.1162/1535350041464874PubMedCrossRef

Meulenbroek RA, Sargent KL, Lunde J, Jasmin BJ, Parks RJ: Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 2004, 9: 617-624. 10.1016/j.ymthe.2004.01.012PubMedCrossRef

Le LP, Le HN, Nelson AR, Matthews DA, Yamamoto M, Curiel DT: Core labeling of adenovirus with EGFP. Virology 2006, 351: 291-302. 10.1016/j.virol.2006.03.042PubMedPubMedCentralCrossRef

Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M: Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res 2005, 65: 10154-10158. 10.1158/0008-5472.CAN-05-1871PubMedCrossRef

Li J, Le L, Sibley DA, Mathis JM, Curiel DT: Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology 2005, 338: 247-258. 10.1016/j.virol.2005.04.005PubMedCrossRef

Kimball KJ, Rivera AA, Zinn KR, Icyuz M, Saini V, Li J, Zhu ZB, Siegal GP, Douglas JT, Curiel DT, Alvarez RD, Borovjagin AV: Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. Mol Imaging 2009, 8: 264-277.PubMedPubMedCentral

10.

Hurst HC, Jones NC: Identification of factors that interact with the E1A-inducible adenovirus E3 promoter. Genes Dev 1987, 1: 1132-1146. 10.1101/gad.1.10.1132PubMedCrossRef

11.

Kornuc M, Kliewer S, Garcia J, Harrich D, Li C, Gaynor R: Adenovirus early region 3 promoter regulation by E1A/E1B is independent of alterations in DNA binding and gene activation of CREB/ATF and AP1. J Virol 1990, 64: 2004-2013.PubMedPubMedCentral

12.

Weeks DL, Jones NC: Adenovirus E3-early promoter: sequences required for activation by E1A. Nucleic Acids Res 1985, 13: 5389-5402. 10.1093/nar/13.14.5389PubMedPubMedCentralCrossRef

13.

Ugai H, Wang M, Le LP, Matthews DA, Yamamoto M, Curiel DT: In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection. J Mol Biol 2010, 395: 55-78. 10.1016/j.jmb.2009.10.034PubMedPubMedCentralCrossRef

14.

Sargent KL, Meulenbroek RA, Parks RJ: Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J Virol 2004, 78: 5032-5037. 10.1128/JVI.78.10.5032-5037.2004PubMedPubMedCentralCrossRef

15.

Sargent KL, Ng P, Evelegh C, Graham FL, Parks RJ: Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors. Gene Ther 2004, 11: 504-511. 10.1038/sj.gt.3302107PubMedCrossRef

16.

Le LP, Le HN, Dmitriev IP, Davydova JG, Gavrikova T, Yamamoto S, Curiel DT, Yamamoto M: Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst 2006, 98: 203-214.PubMedCrossRef

17.

Green M, Pina M, Kimes RC: Biochemical studies on adenovirus multiplication. XII. Plaquing efficiencies of purified human adenoviruses. Virology 1967, 31: 562-565. 10.1016/0042-6822(67)90241-3PubMedCrossRef

18.

Webster A, Russell S, Talbot P, Russell WC, Kemp GD: Characterization of the adenovirus proteinase: substrate specificity. J Gen Virol 1989,70(Pt 12):3225-3234. 10.1099/0022-1317-70-12-3225PubMedCrossRef

19.

Ruzindana-Umunyana A, Imbeault L, Weber JM: Substrate specificity of adenovirus protease. Virus Res 2002, 89: 41-52. 10.1016/S0168-1702(02)00111-9PubMedCrossRef

20.

Zhu ZB, Lu B, Park M, Makhija SK, Numnum TM, Kendrick JE, Wang M, Tsuruta Y, Fisher P, Alvarez RD, Zhou F, Siegal GP, Wu H, Curiel DT: Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Int J Oncol 2008, 32: 1179-1188.PubMed

21.

Sarkioja M, Kanerva A, Salo J, Kangasniemi L, Eriksson M, Raki M, Ranki T, Hakkarainen T, Hemminki A: Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer 2006, 107: 1578-1588. 10.1002/cncr.22209PubMedCrossRef

22.

Ranki T, Kanerva A, Ristimaki A, Hakkarainen T, Sarkioja M, Kangasniemi L, Raki M, Laakkonen P, Goodison S, Hemminki A: A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther 2007, 14: 58-67. 10.1038/sj.gt.3302830PubMedPubMedCentralCrossRef

23.

Kanerva A, Zinn KR, Peng KW, Ranki T, Kangasniemi L, Chaudhuri TR, Desmond RA, Wang M, Takayama K, Hakkarainen T, Alfthan H, Stenman UH, Curiel DT, Hemminki A: Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 2005, 12: 87-94. 10.1038/sj.gt.3302387PubMedCrossRef

24.

Ricci D, Mennander AA, Pham LD, Rao VP, Miyagi N, Byrne GW, Russell SJ, McGregor CG: Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts. Eur J Cardiothorac Surg 2008, 33: 32-39. 10.1016/j.ejcts.2007.09.033PubMedPubMedCentralCrossRef

25.

Li H, Li JZ, Helm GA, Pan D: Non-invasive imaging of firefly luciferase reporter gene expression using bioluminescence imaging in human prostate cancer models. Biotechnol Appl Biochem 2007, 46: 179-184. 10.1042/BA20060081PubMedCrossRef

26.

MacLaren DC, Gambhir SS, Satyamurthy N, Barrio JR, Sharfstein S, Toyokuni T, Wu L, Berk AJ, Cherry SR, Phelps ME, Herschman HR: Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999, 6: 785-791. 10.1038/sj.gt.3300877PubMedCrossRef

27.

Fontanellas A, Hervas-Stubbs S, Sampedro A, Collantes M, Azpilicueta A, Mauleon I, Paneda A, Quincoces G, Prieto J, Melero I, Penuelas I: PET imaging of thymidine kinase gene expression in the liver of non-human primates following systemic delivery of an adenoviral vector. Gene Ther 2009, 16: 136-141. 10.1038/gt.2008.122PubMedCrossRef

28.

Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E, Ranki T, Pisto T, Sarkioja M, Desmond RA, Kanerva A, Hemminki A: Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther 2007, 14: 902-911. 10.1038/sj.gt.3302949PubMedCrossRef

29.

Pham L, Nakamura T, Gabriela RA, Carlson SK, Bailey KR, Peng KW, Russell SJ: Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. J Gene Med 2009, 11: 197-206. 10.1002/jgm.1289PubMedPubMedCentralCrossRef

30.

Lesniak MS, Langer R, Brem H: Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 2001, 1: 210-216. 10.1007/s11910-001-0020-zPubMedCrossRef

31.

Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352: 987-996. 10.1056/NEJMoa043330PubMedCrossRef

32.

Lesniak MS: Novel advances in drug delivery to brain cancer, Technol. Cancer Res Treat 2005, 4: 417-428.CrossRef

33.

Kirn D: Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000, 19: 6660-6669. 10.1038/sj.onc.1204094PubMedCrossRef

34.

Kirn D, Martuza RL, Zwiebel J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001, 7: 781-787. 10.1038/89901PubMedCrossRef

35.

Worgall S, Wolff G, Falck-Pedersen E, Crystal RG: Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997, 8: 37-44. 10.1089/hum.1997.8.1-37PubMedCrossRef

36.

Sonabend AM, Ulasov IV, Lesniak MS: Conditionally replicative adenoviral vectors for malignant glioma. Rev Med Virol 2006, 16: 99-115. 10.1002/rmv.490PubMedCrossRef

37.

Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS: Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer 2009, 100: 1154-1164. 10.1038/sj.bjc.6604969PubMedPubMedCentralCrossRef

38.

Idema S, Lamfers ML, van BV, Noske DP, Heukelom S, Moeniralm S, Gerritsen WR, Vandertop WP, Dirven CM: AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. J Gene Med 2007, 9: 1046-1056. 10.1002/jgm.1113PubMedCrossRef

39.

Graat HC, Witlox MA, Schagen FH, Kaspers GJ, Helder MN, Bras J, Schaap GR, Gerritsen WR, Wuisman PI, van BV: Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer 2006, 94: 1837-1844. 10.1038/sj.bjc.6603189PubMedPubMedCentralCrossRef

40.

Roth JC, Curiel DT, Pereboeva L: Cell vehicle targeting strategies. Gene Ther 2008, 15: 716-729. 10.1038/gt.2008.38PubMedCrossRef

41.

Cody JJ, Douglas JT: Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009, 16: 473-488. 10.1038/cgt.2009.3PubMedPubMedCentralCrossRef

42.

Martin-Fernandez M, Longshaw SV, Kirby I, Santis G, Tobin MJ, Clarke DT, Jones GR: Adenovirus type-5 entry and disassembly followed in living cells by FRET, fluorescence anisotropy, and FLIM. Biophys J 2004, 87: 1316-1327. 10.1529/biophysj.103.035444PubMedPubMedCentralCrossRef

43.

Tang Y, Le LP, Matthews QL, Han T, Wu H, Curiel DT: Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 2008, 377: 391-400. 10.1016/j.virol.2008.04.023PubMedCrossRef

44.

Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT, Nettelbeck DM: Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 2004, 320: 121-134. 10.1016/j.virol.2003.11.028PubMedCrossRef

45.

Stewart PL: Adenovirus Structure. In Adenoviral Vectors for Gene therapy Edited by: Curiel DT, Douglas JT. 2002, 1-18. full_textCrossRef

46.

Bhatti AR, Weber J: Protease of adenovirus type 2. Subcellular localization. J Biol Chem 1979, 254: 12265-12268.PubMed

47.

Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001, 19: 289-298.PubMed

48.

Freytag SO, Khil M, Stricker H, Peabody J, Menon M, Peralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K, Lu M, guilar-Cordova E, Kim JH: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002, 62: 4968-4976.PubMed

49.

Reid T, Warren R, Kirn D: Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002, 9: 979-986. 10.1038/sj.cgt.7700539PubMedCrossRef

Title: Evaluation of adenovirus capsid labeling versus transgene expression
Authors: Jing Li
Aiman Fatima
Svetlana Komarova
Hideyo Ugai
Priyanka Uprety
Justin C Roth
Minghui Wang
Robert A Oster
David T Curiel
Qiana L Matthews
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-7-21

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Evaluation of adenovirus capsid labeling versus transgene expression

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

A multiplex reverse transcription-nested polymerase chain reaction for detection and differentiation of wild-type and vaccine strains of canine distemper virus

Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy

A Functional Henipavirus Envelope Glycoprotein Pseudotyped Lentivirus Assay System

Early detection of Varicella-Zoster Virus (VZV)-specific T-cells before seroconversion in primary varicella infection: case report

Proteome changes of lungs artificially infected with H-PRRSV and N-PRRSV by two-dimensional fluorescence difference gel electrophoresis

A real-time RT-PCR for detection of clade 1 and 2 H5N1 Influenza A virus using Locked Nucleic Acid (LNA) TaqMan probes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page